Total hip arthroplasty (THA) is accompanied by substantial blood loss, averaging 1,000--2,000 ml[@b1][@b2][@b3] and a decline of 3.0 to 4.0 g/dl in haemoglobin levels[@b3]. Moreover, hidden blood loss can account for 60% of total blood loss, ranging from 612 to 1,603 ml[@b4]. This substantial blood loss potentially contributes to delayed postoperative rehabilitation, a longer hospital stay, and even mortality. Thus, patients undergoing THA typically require transfusion. However, with an increased awareness of the potential deleterious effects of allogenic blood transfusion, including infection, transfusion-associated lung injury and circulatory overload, and mortality[@b5][@b6][@b7][@b8][@b9][@b10], a consensus has emerged on perioperative blood management that allogenic blood transfusion should be minimized. Nevertheless, the rate of allogenic blood transfusions remains high due to the growing number of THA procedures[@b1][@b11]. Saleh *et al.* stated that the increase in allogenic transfusion is associated with increased complications, longer hospital stays, and increased cost. Thus, they recommended the effective utilization of blood conservation methods[@b1].

Autologous blood transfusion, including preoperative autologous blood donation, intraoperative blood salvage and postoperative autotransfusion drain (PATD), is considered effective in reducing allogenic blood transfusion and its underlying risks[@b9][@b12][@b13]. In several autologous transfusions, PATD is considered relatively simple to implement and potentially cost-effective[@b14][@b15]. Such drainage devices collect postoperatively shed blood and then retransfuse the shed blood (washed or unwashed) to patients within 6 hours postoperatively. Previous studies have demonstrated that PATD significantly reduces the rate of allogenic transfusion and results in reduced blood loss[@b16][@b17][@b18][@b19][@b20]. However, the use of the PATD remains controversial, and some studies have questioned its effectivenss[@b21][@b22][@b23][@b24][@b25]. To resolve the existing uncertainties, we performed a meta-analysis to evaluate the efficacy and safety of PATD compared with a closed-suction drain (CSD).

Results
=======

Study selection
---------------

A total of 277 records were searched via database and manual searches. After a thorough screening of titles and abstracts, 251 records were excluded. The remaining 26 articles were assessed in a full-text review. Finally, thirteen studies[@b16][@b17][@b18][@b21][@b22][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33] involving 1,424 participants met the inclusion criteria and were included in the meta-analysis ([Fig. 1](#f1){ref-type="fig"}).

Characteristics of included studies
-----------------------------------

The characteristics of the included studies are listed in [Table 1](#t1){ref-type="table"}. Eight studies performed only primary THA[@b16][@b17][@b18][@b21][@b22][@b27][@b28][@b29], one study performed only revision surgery[@b30], and the remaining studies performed both. Four studies involved total knee arthroplasty[@b18][@b28][@b31][@b33]; however, data related to THA were extracted. In one three-arm study[@b31], two different postoperative autotransfusion devices were compared with CSD. We combined these two autotransfusion groups according to the Cochrane Handbook[@b34].

Risk of bias
------------

The assessment of risk of bias is shown in [Fig. 2](#f2){ref-type="fig"}. Random sequence generation was mentioned in all included studies. Ten of the studies detailed the methods of randomization used[@b16][@b17][@b18][@b21][@b22][@b26][@b27][@b28][@b31][@b32]; however, two used inadequate randomization (one was randomized by month of birth[@b22], and another was randomized by hospital number[@b32]), which led to categorization as "high risk". Six studies described adequate allocation concealment[@b16][@b17][@b18][@b21][@b26][@b31]. Only two studies described the blinding methods used: one performed double blinding of surgeons and assessors[@b16], and another performed blinding of the study assessors[@b26]. Two studies had a high risk of incomplete outcome data[@b27][@b31] due to a lack of details in some adverse events. In addition, we categorized three studies as of unclear risk based on other biases due to funding from device manufacturers[@b26][@b30][@b31].

Outcomes of the meta-analysis
-----------------------------

All data regarding transfusion rate, total blood loss, postoperative Hb, length of hospital stay, febrile reaction, infection, wound problems and serious adverse events were pooled for comparison. The overall outcomes are summarized in [Table 2](#t2){ref-type="table"}.

Rate of allogenic transfusion
-----------------------------

All thirteen studies[@b16][@b17][@b18][@b21][@b22][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33] reported the rate of allogenic transfusion; the data from these studies were pooled. The pooled results showed that PATD significantly reduced the rate of allogenic transfusion (RR = 0.56; 95% CI: 0.40 to 0.77; p = 0.0004; [Fig. 3a](#f3){ref-type="fig"}), with a small to moderate heterogeneity (p = 0.07, I^2^ = 40%). Moreover, when only high-quality studies were pooled, the result showed the same effect in the PATD group (RR = 0.59; 95% CI: 0.42 to 0.83; p = 0.003; [Fig. 3b](#f3){ref-type="fig"}), with no significant heterogeneity (p = 0.81, I^2^ = 0%).

Total blood loss
----------------

Data regarding total blood loss were only available in two studies[@b16][@b26]. No significant heterogeneity was found (p = 0.89, I^2^ = 0%). The pooled results showed that total blood loss was lower in patients treated with PATD (MD = −196.04; 95% CI: −311.01 to −81.07; p = 0.0008; [Fig. 4](#f4){ref-type="fig"}).

Postoperative haemoglobin level
-------------------------------

Six studies[@b16][@b17][@b21][@b27][@b28][@b30] reported the Hb levels on days 1--3 after surgery. Therefore, we performed subgroup meta-analyses to compare the Hb levels based on the date. There were no significant heterogeneities among the subgroups (p = 0.56, I^2^ = 0%; p = 0.53, I^2^ = 0%; p = 0.2, I^2^ = 34%; respectively). On the first postoperative day, the PATD group maintained a higher level (MD = 0.28; 95% CI: 0.06 to 0.49; p = 0.01; [Fig. 5](#f5){ref-type="fig"}). However, there were no significant differences between the two groups on postoperative days 2 or 3 (MD = 0.29; 95% CI: −0.02 to 0.60; p = 0.07; MD = 0.26; 95% CI: −0.04 to 0.56; p = 0.09; respectively; [Fig. 5](#f5){ref-type="fig"}).

Length of hospital stay
-----------------------

Six studies[@b16][@b17][@b21][@b27][@b30][@b31] reported the length of hospital stay. There was no difference between the two groups (MD = −0.18; 95% CI: −0.61 to 0.25; p = 0.41; [Fig. 6](#f6){ref-type="fig"}), and heterogeneity was low (p = 0.15, I^2^ = 39%).

Febrile reaction
----------------

Five studies[@b16][@b17][@b28][@b30][@b31] reported febrile reactions. No significant difference was observed between the two groups (RR = 1.26; 95% CI: 0.95 to 1.67; p = 0.11; [Fig. 7](#f7){ref-type="fig"}), and heterogeneity was low (p = 0.25, I^2^ = 25%).

Infection
---------

Infections were documented in five studies[@b16][@b17][@b26][@b27][@b30]. The pooled results showed no significant differences between the two groups in terms of infection (RR = 0.95; 95% CI: 0.54 to 1.65; p = 0.84; [Fig. 8](#f8){ref-type="fig"}); no significant heterogeneity was observed (p = 0.74, I^2^ = 0%).

Wound problems
--------------

Wound problems were reported in five studies[@b17][@b21][@b22][@b26][@b30]. The two groups did not differ significantly (RR = 1.07; 95% CI: 0.87 to 1.33; p = 0.53; [Fig. 9](#f9){ref-type="fig"}), and no significant heterogeneity was observed (p = 0.96, I^2^ = 0%).

Serious adverse events
----------------------

Only three studies[@b16][@b26][@b27] reported serious adverse events, including one death in the PATD group and one pulmonary embolism and two deaths in the CSD group. No significant heterogeneity was observed (p = 0.43, I^2^ = 0%). No significant difference was found between the two groups (RR = 0.59; 95% CI: 0.10 to 3.58; p = 0.57; [Fig. 10](#f10){ref-type="fig"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed by removing each study individually to identify whether the pooled results changed. All results were stable except postoperative Hb levels. On postoperative day 1, the difference between groups became statistically insignificant after the removal of one study[@b16]; in addition, the removal of another study[@b27] on postoperative day 3 reduced I^2^ to 0% but resulted in a significant difference between groups. In addition, two studies[@b22][@b29] accounted for the main source of heterogeneity of the allogenic transfusion rate; removing these two studies resulted in a large reduction of heterogeneity (I^2^ decreased to 0%); however, the results still suggested that PATD reduced the transfusion rate.

Publication bias
----------------

Publication bias was evaluated using Begg's test and Harbord's test (or Egger's test). There was no evidence for significant publication bias among most of the included studies. Details are shown in [Table 3](#t3){ref-type="table"}.

Discussion
==========

Although restrictive blood management and several transfusion alternatives have been developed for minimizing exposure to allogenic blood[@b35][@b36][@b37][@b38][@b39][@b40][@b41], an increasing rate of allogenic transfusion remains following THA due to a number of identifiable risk factors, such as female gender, older age, black race, medical insurance and previous anaemia[@b1][@b5][@b42][@b43]. Moreover, under certain circumstances, allogenic transfusion is not feasible, such as with Jehovah's Witnesses who refuse allogenic blood and patients with rare blood types. Optimizing the use of blood conservation potentially resolves such conditions; nevertheless, there is little evidence regarding the efficacy of PATD.

Previous meta-analyses[@b12][@b20][@b24][@b44] have investigated the efficacy and safety of cell salvage in THA. However, the strength of these meta-analyses was weakened by poor methodological quality or other limitations, and the conclusions were inconsistent. The studies by Carless *et al.* and Haien *et al.* combined several types of orthopaedic surgery, which inevitably resulted in clinical heterogeneity because a tourniquet is commonly used in total knee arthroplasty. Moreover, most included studies had a high risk of bias. In Li *et al.*'s meta-analysis[@b24], PATD showed no effect on reducing the transfusion rate but appeared to be associated with less total blood loss and lower superficial infection. However, few studies were included to analyse the transfusion rate as well as certain other outcomes. In a more recent study[@b44], inconsistent results were obtained; when all studies were pooled, the conclusion favoured cell salvage, but the pooled results of recent trials (2010 to 2012) showed no difference between groups. Because the authors subjectively considered that studies published after 2010 had a lower risk of bias, the subgroup analyses appeared to explain the clinical significance and the substantial heterogeneity in other subgroups with difficulty. Furthermore, the analysis might have neglected some high-quality trials published before 2010 or included recent trials of poor quality. In addition, the authors only compared the transfusion rate; other data of clinical significance were not analysed. Given the defects found in previous studies, we performed the present meta-analysis to determine whether PATD could be of greater benefit to THA patients than CSD. We eliminated potential confounding factors from total knee arthroplasty and intraoperative cell salvage, which controlled for the clinical heterogeneity of the included studies. Moreover, the results of high-quality studies strengthened the conclusion.

To our knowledge, the current study is the largest meta-analysis that has independently investigated the use of PATD after THA. Thirteen eligible RCTs, including 1,424 participants, were included in our meta-analysis to evaluate the efficacy and safety of PATD.

Overall, the most important findings were that PATD significantly reduces the rate of allogenic blood transfusion. PATD is associated with a 44% reduction in the exposure rate of allogenic blood. Moreover, the pooled results of high-quality studies showed a similar effect (a 41% reduction of RR) with no significant heterogeneity (I^2^ = 0, p = 0.81). A recent large cohort study investigated 2,087,423 patients undergoing THA who received allogenic transfusion. The results showed that allogenic transfusion was associated with a longer hospital stay, increased costs, and worse surgical and medical outcomes[@b1]. Another study analysed data from more than 12,000 patients who underwent THA or total knee arthroplasty. That study also demonstrated that allogenic transfusion was significantly associated with a higher risk of infection[@b10]. Therefore, the reduction of allogenic transfusion could potentially decrease the risk of numerous comorbidities and total costs. Although different transfusion management strategies may affect the transfusion rate, in the high-quality studies, restrictive transfusion triggers were used and the transfusion rate was still reduced, indicating that PATD provided an independent effect; this conclusion is strengthened by the methodological quality.

Increased allogenic transfusion is associated with increased blood loss[@b45]. Total blood loss was shown to be lower in the PATD group, a finding that might account for the lower allogenic transfusion rate. Nonetheless, only two studies reported the calculated blood loss, which considers hidden blood loss[@b3][@b4]; thus, it is difficult to draw a conclusion due to the small number of included studies. Other studies reporting estimated blood loss were not available to pool the data.

Although transfusion decisions should consider various factors, haemoglobin concentration remains an important indicator[@b46][@b47]. A higher postoperative Hb level is correlated with a lower transfusion rate, better early functional recovery, and higher patient satisfaction[@b16][@b48]. In this meta-analysis, we found that the PATD group maintained a higher Hb level on the first postoperative day, but no differences were present on the next two days. A potential explanation for this finding is that PATD was only used within 6 hours after surgery. However, this result changed when subjected to sensitivity analysis, suggesting that it was unstable. Munoz *et al.* indicated that no increase in a patient's Hb levels should be expected due to the lower haemoglobin concentration in postoperatively salvaged blood. Indeed, the retransfusion of shed blood is likely to maintain Hb levels above the transfusion trigger until bleeding stops[@b15].

Regarding length of hospital stay, several studies reported a shorter length of hospital stay in the PATD group[@b14][@b49][@b50]. However, no difference was observed in our study. Given that the length of hospitalization might be correlated with a number of confounding factors, such as patient rehabilitation, comorbidities, and different discharge policies, we recommend that future studies describe the standard of discharge with more details and isolate the potential confounders.

Postoperative shed blood, particularly unwashed blood, may be contaminated with wound material and contains a variety of tissue materials and chemical debris, potentially causing complications, such as febrile reaction, infections, embolism, immune response and even death[@b25][@b51][@b52]. Washed shed blood is considered safer because most bioactive contaminants are removed[@b53][@b54][@b55]; however, washing shed blood is expensive and complex. Nevertheless, studies have suggested that the incidence of adverse events is lower than theoretically predicted[@b15][@b51][@b56]. In addition, with recent improvements in techniques and practices, the use of cell salvage is safe, even in obstetrics or malignancy[@b13]. Similarly, in our study, adverse events showed a low incidence. However, no differences in adverse events between PATD and CSD were observed. This finding may be due to the low incidence; most of the included studies were underpowered to accurately reflect the incidence of adverse events. Therefore, future studies with larger sample sizes are urgently needed to determine the safety of PATD.

In spite of the rigorous protocol of this meta-analysis, several limitations should be taken into account. First, some of the included studies had one or more risks of bias, such as inappropriate randomization, no allocation concealment, lack of blinding, and other shortcomings, which limited the reliability of the outcomes. However, the pooled results of high-quality studies reached the same conclusion, which strengthens our conclusion. Second, the number of studies investigating several outcomes was relatively small because some data were not available; thus, these outcomes may be changed by the findings of future research. Third, there were several transfusion triggers in different studies, which might be a potential source of clinical heterogeneity that affects the results. In addition, the sample sizes of most of the included studies did not have sufficient power to draw a conclusion regarding adverse events, suggesting that further study on this topic is needed.

In conclusion, we found that PATD is effective in reducing the rate of allogenic transfusion in patients undergoing THA; a reduction of RR of more than 40% was found. Moreover, the use of PATD appears to be associated with a higher postoperative Hb level and less total blood loss, without any significant adverse events. Thus, PATD may reduce the exposure to allogenic blood and its underlying risks. The current evidence may guide clinicians in their decisions with regard to transfusion for THA patients. However, due to the limitations of this meta-analysis, we recommend more widely accepted transfusion guidelines, and additional well-designed RCTs with adequate sample sizes and a consolidated standard are needed.

Methods
=======

Search strategy
---------------

A comprehensive search was performed in the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases up to March 2016. The search terms included "autologous blood transfusion", "operative blood salvage", "autotransfusion", "blood salvage", "retransfusion", "arthroplasty, replacement, hip", "total hip arthroplast\*", "total hip replacement\*", and "total hip prosthes\*". The related references in the identified studies were manually searched.

Selection criteria
------------------

The inclusion criteria were as follows: (1) randomized controlled trial; (2) patients treated with primary or revision total hip arthroplasty; (3) PATD compared with CSD; (4) at least one of the key data available, including allogenic transfusion rate, total blood loss, Hb level, length of hospital stay, infection, febrile reaction, wound problems or serious adverse events.

The exclusion criteria were as follows: (1) duplicate articles; (2) cohort studies, case reports, editorials, letters, reviews, and animal experimental studies; (3) data that could not be extracted.

Data extraction
---------------

Two reviewers (HX and JKP) independently extracted the following data from the included studies: authors' names, date of publication, sample size, patients' age and gender, surgery type, allogenic transfusion rate, total blood loss, preoperative and postoperative Hb levels, length of hospital stay, febrile reaction, infection rate, wound problems (wound leakage, haematoma, delayed healing) and severe adverse events (life-threatening events and death). In the event of missing data, we attempted to contact the corresponding authors for details.

Quality assessment
------------------

The methodological quality of the included studies was independently evaluated by two reviewers (HX and HKH) using the Cochrane Collaboration's tool for assessing the risk of bias[@b34]. These domains were selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessments), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other bias (other sources of bias). Any disagreements were resolved by discussion or were arbitrated by the corresponding author (JL).

Statistical analysis
--------------------

Risk ratio (RR) and mean difference (MD) were used to pool dichotomous and continuous data, respectively. The meta-analysis was performed using Review Manager 5.3.5 (Cochrane Collaboration, Oxford, UK). For continuous data presented as the mean with quartile/range, the standard deviations were estimated according to the Cochrane Handbook[@b34] or the method described by Hozo *et al.*[@b57]. Heterogeneity was assessed using the Cochrane Q test and I-square statistic. A sensitivity analysis was performed to identify the source of the heterogeneity. All data were pooled using the random-effects model. Begg's test and Harbord's test (or Egger's test) were used to estimate potential publication bias.
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###### Characteristics of the included studies.

  Author              Date   Sample size   Gender (F/M)   Age (Y)   Preoperative Hb level (g/dL)   Types of surgery                                                                 
  ------------------ ------ ------------- -------------- --------- ------------------------------ ------------------ ----------------- --------------------- ---------------------- -------
  Atay[@b28]          2010       17             19         6/11                 6/13                59.76 ± 15.43      58.95 ± 13.6        13.52 ± 1.07           12.98 ± 1.46         P
  Ayers[@b32]         1995       103           129        125/107          72 (20 to 89)                 12.9              12.9                P & R                                
  Cheung[@b27]        2010       53             52         39/22               30/24                65 (61 to 73)     70.5 (63 to 76)   13.6 (13.0 to 14.4)   13.7 (12.7 to 14.3)      P
  Horstmann[@b16]     2014       56             62         36/20               42/20                  67.6 ± 9.1        69.3 ± 9.5          14.2 ± 1.3             14.1 ± 0.9          P
  Kleinert[@b21]      2012       40             40         19/21               19/21                   66 ± 10            64 ± 11       14.2 (11.4 to 17.1)   14.0 (10.2 to 16.6)      P
  Moonen[@b18]        2007       35             48          NA                   NA                       NA                NA                  NA                     NA              P
  Rollo[@b22]         1995       40             40         16/24               20/20                68 (28 to 87)      64 (39 to 85)            NA                     NA              P
  Slagis[@b33]        1991       24             26          NA                   NA                       NA                NA                  NA                     NA            P & R
  Slappendel[@b30]    2008       91             88         54/37               56/32                   68 ± 10            69 ± 11           13.8 ± 1.4             13.9 ± 1.4          R
  Smith[@b17]         2007       76             82         40/36               42/40               73.5 (52 to 87)    75.5 (46 to 91)   13.61 (9.3 to 17.1)   13.59 (10.3 to 16.5)     P
  So-Osman[@b31]      2006       35             11          NA                   NA                       NA                NA                  NA                     NA            P & R
  Thomassen[@b26]     2012       96            101         69/27               65/36                   67 ± 11            65 ± 12          13.87 ± 1.16           13.98 ± 1.16       P & R
  Tripkovic[@b29]     2008       30             30         16/14               18/12                   68 ± 12            71 ± 11               NA                     NA              P

PATD: postoperative autotransfusion drain; CSD: closed-suction drain; F: female; M: male; Y: years; P: primary arthroplasty; R: revision arthroplasty; NA: data not available.

###### Summary of meta-analysis outcomes.

  Outcomes                  N    Patients(PATD/CSD)         Overall effect          Heterogeneity        
  ------------------------ ---- -------------------- ----------------------------- --------------- ----- ------
  Transfusion rate                                                                                       
   All included studies     13        696/728             0.56 \[0.40, 0.77\]          0.0004       40%   0.07
   High-quality studies     6         320/352             0.59 \[0.42, 0.83\]           0.003       0%    0.81
  Total blood loss          2         152/163         −196.04 \[−311.01, −81.07\]      0.0008       0%    0.89
  Postoperative Hb                                                                                       
   Day 1                    5         292/303             0.28 \[0.06, 0.49\]           0.01        0%    0.56
   Day 2                    2         146/149            0.29 \[−0.02, 0.60\]           0.07        0%    0.53
   Day 3                    5         253/257            0.26 \[−0.04, 0.56\]           0.09        34%   0.2
  Hospital stay             6         351/335            −0.18 \[−0.61, 0.25\]          0.41        39%   0.15
  Febrile reaction          5         275/262             1.26 \[0.95, 1.67\]           0.11        25%   0.25
  Infections                5         372/385             0.95 \[0.54, 1.65\]           0.84        0%    0.74
  Wound problems            5         343/351             1.07 \[0.87, 1.33\]           0.53        0%    0.96
  Serious adverse events    3         205/215             0.59 \[0.10, 3.58\]           0.57        0%    0.43

N: number of studies; RR: risk ratio; MD: mean difference; CI: confidence interval.

###### Assessment of publication bias.

  Outcomes                      N    Begg's test   Harbord's test or Egger's test
  ---------------------------- ---- ------------- --------------------------------
  Allogenic transfusion rate                      
   All included studies         13    p = 0.583               p = 0.35
   High-quality studies         6     p = 0.26               p = 0.247
  Total blood loss              2     p = 1.000    NA[\*](#t3-fn1){ref-type="fn"}
  Postoperative Hb                                
   Day 1                        5     p = 1.000              p = 0.852
   Day 2                        2     p = 1.000    NA[\*](#t3-fn1){ref-type="fn"}
   Day 3                        5     p = 0.806              p = 0.378
  Length of hospital stay       6     p = 0.260              p = 0.137
  Febrile reaction              5     p = 1.000              p = 0.926
  Infection                     5     p = 0.221              p = 0.388
  Wound problems                5     p = 0.806              p = 0.907
  Serious adverse events        3     p = 0.296              p = 0.616

N: number of studies; NA: data not available; \*Assessment of publication bias could not be performed because the number of studies was less than 3.
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